DesmoMelt is a sublingual oral lyophilisate formulation of desmopressin which quickly dissolves when taken.1,2 It is licensed for the treatment of primary nocturnal enuresis (PNE) in children and adults aged 5 to 65.1
A statistically significant preference for DesmoMelt compared with tablets has been seen in children aged 5–11 years2
DesmoMelt is well accepted by children of various ages and facilitates early intervention,2 providing an effective and convenient solution to primary nocturnal enuresis and helping children and families return to a normal life.
Statistically significant superior antidiuretic effect at 3–8 hours after dosing when compared with tablet3
Due to the superior pharmacodynamic characteristics of the melt formulation, more than 25% of patients had a higher diuresis rate with the tablet vs. melt formulation, which was significantly different from hours 3 to 8 after dosing.3
The value of compliance2 with no significant cost burden to NHS4
DesmoMelt is associated with a numerically higher compliance rate than the tablet (94.5% vs. 88.9%; not significant) and retains similar levels of efficacy and safety at lower dosing levels.2
In a study comparing children’s response rates after 2 months’ treatment, overall response rates were better with DesmoMelt4
A single dose (120mcg) of DesmoMelt should be taken before bedtime for a period of 3 months, followed by a 1 week drug-free period to assess results. If symptoms persist, the treatment cycle should be repeated.1
If needed, the dose taken can be increased to 240mcg.1
For more information about the benefits of DesmoMelt, download our short leaflet.
Prescribing Information and Adverse Event Reporting
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Ferring Pharmaceuticals Ltd.
Tel: 0844 931 0050, Email: firstname.lastname@example.org